TS-104 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors.
The main goals of this study are to:
* Find the recommended dose of TS-104 that can safely be given to participants
* Learn more about the side effects of TS-104
* Learn more about the effectiveness of TS-104
* Learn more about the pharmacokinetics of TS-104
Are You a Good Fit for This Trial?
This trial is for adults (18+) with certain advanced cancers, such as ovarian, endometrial, gastric, esophageal, non-small cell lung cancer, or head and neck cancers. Participants must have measurable disease and be willing to provide tumor samples and informed consent.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- TS-104
Trial Overview
The study tests TS-104, a new peptide drug conjugate given alone to people with select advanced solid tumors. The main goals are to find a safe dose and learn about its side effects and how it works in the body.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
TS-104 will be administered either 2Q3W (i.e. on days 1 and 8 every 21 days) or Q2W (i.e. on days 1 and 15 every 28 days)
TS-104 will be administered Q2W (i.e. on days 1 and 15 every 28 days)
TS-104 will be administered 2Q3W (i.e. on days 1 and 8 every 21 days)
Find a Clinic Near You
Who Is Running the Clinical Trial?
TwoStep Therapeutics, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.